×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
NASDAQ:MXCT

MaxCyte Stock Forecast, Price & News

$4.83
-0.42 (-8.00%)
(As of 06/29/2022 03:59 PM ET)
Add
Compare
Today's Range
$4.77
$5.20
50-Day Range
$3.59
$5.84
52-Week Range
$3.36
$17.44
Volume
32,044 shs
Average Volume
623,912 shs
Market Capitalization
$490.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

MXCT Stock Forecast (MarketRank)

Overall MarketRank

0.33 out of 5 stars

Medical Sector

1340th out of 1,432 stocks

Commercial Physical Research Industry

21st out of 24 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
MaxCyte logo

About MaxCyte (NASDAQ:MXCT)

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

MXCT Stock News Headlines

MaxCyte (MXCT) vs. Its Peers Head to Head Survey
MaxCyte (MXCT) vs. The Competition Head to Head Survey
Head-To-Head Survey: MaxCyte (MXCT) vs. The Competition
Head-To-Head Contrast: MaxCyte (MXCT) versus Its Competitors
Head-To-Head Review: MaxCyte (MXCT) versus Its Rivals
MaxCyte (MXCT) and Its Rivals Critical Review
Contrasting MaxCyte (MXCT) & The Competition
MaxCyte (MXCT) and Its Peers Head to Head Analysis
Analyzing MaxCyte (MXCT) & Its Peers
See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MXCT
Employees
84
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
6/29/2022
Next Earnings (Estimated)
9/12/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-19.08 million
Pretax Margin
-41.15%

Debt

Sales & Book Value

Annual Sales
$33.89 million
Book Value
$2.61 per share

Miscellaneous

Free Float
96,351,000
Market Cap
$490.44 million
Optionable
Optionable
Beta
N/A














MaxCyte Frequently Asked Questions

Should I buy or sell MaxCyte stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MaxCyte stock.
View analyst ratings for MaxCyte
or view top-rated stocks.

How has MaxCyte's stock performed in 2022?

MaxCyte's stock was trading at $6.43 at the start of the year. Since then, MXCT shares have decreased by 24.9% and is now trading at $4.83.
View the best growth stocks for 2022 here
.

When is MaxCyte's next earnings date?

MaxCyte is scheduled to release its next quarterly earnings announcement on Monday, September 12th 2022.
View our earnings forecast for MaxCyte
.

How were MaxCyte's earnings last quarter?

MaxCyte, Inc. (NASDAQ:MXCT) posted its quarterly earnings results on Monday, May, 9th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. The company earned $11.59 million during the quarter, compared to the consensus estimate of $11 million. MaxCyte had a negative net margin of 41.15% and a negative trailing twelve-month return on equity of 7.39%.
View MaxCyte's earnings history
.

What guidance has MaxCyte issued on next quarter's earnings?

MaxCyte issued an update on its first quarter 2022 earnings guidance on Tuesday, April, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11 M-, compared to the consensus revenue estimate of $8.46 million.

Who are MaxCyte's key executives?

MaxCyte's management team includes the following people:
  • Mr. Douglas Arthur Doerfler, Founder, Pres, CEO & Exec. Director (Age 66, Pay $1.39M)
  • Mr. Ronald Evan Holtz CPA, Ph.D., Chief Financial Officer (Age 64, Pay $649.38k)
  • Dr. J. Stark Thompson Ph.D., Consultant (Age 80, Pay $84.71k)
  • Dr. Cenk Sumen, Chief Scientific Officer (Age 49)
  • Mr. Sean Menarguez, Director of Investor Relations
  • Mr. Maher Masoud, Exec. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Thomas Michael Ross, Exec. VP of Global Sales (Age 61)
  • Mr. Kevin Gutshall, VP of Strategy & Corp. Devel.
  • Dr. James Brady Ph.D., Sr. VP of Technical Applications & Customer Support
  • Dr. Sarah Haecker Meeks Ph.D., Sr. VP of Bus. Devel.

When did MaxCyte IPO?

(MXCT) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.

What is MaxCyte's stock symbol?

MaxCyte trades on the NASDAQ under the ticker symbol "MXCT."

Who are MaxCyte's major shareholders?

MaxCyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.36%), Vitruvian Partners LLP (4.32%), Vanguard Group Inc. (3.23%), River & Mercantile Asset Management LLP (2.07%), Massachusetts Financial Services Co. MA (1.84%) and American Century Companies Inc. (1.63%).

Which institutional investors are selling MaxCyte stock?

MXCT stock was sold by a variety of institutional investors in the last quarter, including Montanaro Asset Management Ltd, River & Mercantile Asset Management LLP, Nicholas Investment Partners LP, RTW Investments LP, Royce & Associates LP, Apis Capital Advisors LLC, TD Asset Management Inc., and Bank of New York Mellon Corp.

Which institutional investors are buying MaxCyte stock?

MXCT stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Vitruvian Partners LLP, Goldman Sachs Group Inc., Grandeur Peak Global Advisors LLC, State Street Corp, BlackRock Inc., Vanguard Group Inc., and First Light Asset Management LLC.

How do I buy shares of MaxCyte?

Shares of MXCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MaxCyte's stock price today?

One share of MXCT stock can currently be purchased for approximately $4.83.

How much money does MaxCyte make?

MaxCyte (NASDAQ:MXCT) has a market capitalization of $490.44 million and generates $33.89 million in revenue each year. The company earns $-19.08 million in net income (profit) each year or ($0.170010) on an earnings per share basis.

How many employees does MaxCyte have?

MaxCyte employs 84 workers across the globe.

How can I contact MaxCyte?

MaxCyte's mailing address is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. The official website for MaxCyte is maxcyte.com. The company can be reached via phone at 301 944 1700, via email at [email protected], or via fax at 301-944-1703.

This page (NASDAQ:MXCT) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.